FDA approves Opus Genetics’ eye drops for presbyopia treatment

Opus Genetics (NASDAQ:IRD) received FDA clearance for its gene therapy OPGx-RDH12, targeting RDH12-associated Leber congenital amaurosis. The company plans to start a Phase 1/2 trial this quarter. The therapy aims to restore retinal function in a rare inherited disease affecting 30,900 people globally. Opus Genetics collaborates with the Global RDH12 Alliance, which committed up to $1.6 million for development.

Opus Genetics (IRD) received FDA approval to expand Ryzumvi's use to adults with presbyopia, a milestone that triggers a payment from partner Viatris (VTRS). IRD's P/S ratio is 29.84, far above its historical median, reflecting high growth expectations despite its unprofitability. The company's GF Score is 21, indicating financial and operational challenges, and insiders have sold $19.3M in shares over the past year.

Opus Genetics (IRD) received FDA approval for its phentolamine ophthalmic solution, triggering a licensing agreement payment. The company trades at a high P/S ratio of 30.33, reflecting growth expectations despite financial challenges. Insider activity shows significant selling. The FDA approval follows successful clinical trials for presbyopia treatment.

Opus Genetics (IRD) received FDA approval for phentolamine ophthalmic solution 0.75% to treat presbyopia, an age-related vision condition. The approval follows positive Phase 3 trial results and triggers a milestone payment. Viatris holds U.S. commercialization rights. The drug is marketed as RYZUMVI, with presbyopia as a new indication.

Opus Genetics (IRD) received FDA approval to expand its RYZUMVI drug to treat presbyopia in adults. This triggers a milestone payment under its commercialization deal with Viatris. The company shifts from R&D to commercial economics. Next steps include milestone disclosure, launch timing, pricing, and prescription uptake metrics.

The FDA approved Opus Genetics' phentolamine ophthalmic solution (RYZUMVI®) for age-related near-vision loss (presbyopia). The approval, supported by Phase 3 trial results, triggers a milestone payment to Opus Genetics. The company has a licensing agreement with Viatris Inc. for the drug's development.